FDA OKs Biogen Alzheimer's Drug Despite Evidence Issue
The U.S. Food and Drug Administration on Monday approved Biogen's Alzheimer's drug aducanumab, despite an advisory panel's call that the agency shouldn't be so quick to embrace the biotech company's claims...To view the full article, register now.
Already a subscriber? Click here to view full article